Form 4: Anaptysbio Director Sells Shares
Insider Transaction (Form 4)
Hollings Renton, a Director of Anaptysbio, Inc, sold 5,000 shares of common stock on October 1, 2026 for $49.87 per share.
Summary
- Option exercise/conversion: acquired 5,000 Common Stock at $18.03 ($90,150) on October 1, 2026; holds 15,995 after (Direct).
- Open-market sale: disposed of 5,000 Common Stock at $49.87 ($249,372) on October 1, 2026; holds 10,995 after (Direct).
- Option exercise/conversion: disposed of 5,000 Common Stock on October 1, 2026; holds 10,000 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $249,372 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Hollings Renton — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock | 5,000 | $18 | $90.2K | 15,995 |
| 2026-10-01 | Open-market sale | Common Stock | 5,000 | $50 | $249.4K | 10,995 |
| 2026-10-01 | Option exercise/conversion | Common Stock | 5,000 | — | — | 10,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (5,000 shares) |
| 2026-10-01 | Open-market sale (5,000 shares) |
| 2026-10-01 | Option exercise/conversion (5,000 shares) |
Keywords
insider transaction, Form 4, ANAB, ANAPTYSBIO, INC, bearish, Hollings Renton
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.